HuMax-CD4

DRUG4 trials

Sponsors

Genmab, Emergent BioSolutions

Conditions

Cutaneous T-Cell LymphomaRheumatoid ArthritisT Cell Lymphoma

Phase 2

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

TerminatedNCT00042406

GenmabRheumatoid Arthritis

Start: 2002-03-04End: 2003-03-31Updated: 2023-04-28

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

TerminatedNCT00042406

GenmabRheumatoid Arthritis

Start: 2002-03-04End: 2003-03-31Updated: 2023-04-28

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

CompletedNCT00071071

GenmabCutaneous T-Cell Lymphoma

Start: 2003-04-30End: 2004-05-05Updated: 2023-05-18

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

CompletedNCT00071084

GenmabCutaneous T-Cell Lymphoma

Start: 2003-05-27End: 2004-06-29Updated: 2023-04-28

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

CompletedNCT00877656

Emergent BioSolutionsT Cell Lymphoma

Start: 2005-08-31End: 2008-12-31Updated: 2024-03-18